Valeritas (VLRX) Upgraded to “Sell” by ValuEngine

Valeritas (NASDAQ:VLRX) was upgraded by investment analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a note issued to investors on Friday.

Valeritas (VLRX) opened at $3.09 on Friday. The company has a debt-to-equity ratio of 3.54, a current ratio of 3.88 and a quick ratio of 3.20. Valeritas has a 1 year low of $2.00 and a 1 year high of $40.00.

Valeritas (NASDAQ:VLRX) last issued its quarterly earnings results on Wednesday, November 8th. The company reported ($1.62) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.84) by $0.22. Valeritas had a negative return on equity of 820.08% and a negative net margin of 229.55%. equities analysts anticipate that Valeritas will post -8.31 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Valeritas (VLRX) Upgraded to “Sell” by ValuEngine” was reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at

About Valeritas

Valeritas, Inc is a United States-based company, which is engaged in developing and commercializing treatment solutions that contribute to clinical outcomes for patients. The Company’s portfolio includes V-Go disposable insulin delivery device, which is distributed through retail pharmacy. Its V-Go delivers insulin at a continuous preset basal rate and bolus dosing for adults with Type 2 diabetes requiring insulin.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Valeritas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas and related companies with's FREE daily email newsletter.

Leave a Reply